PAX5 and prostate cancer: Finally, we validated Pax5 expression in tissue microarrays (TMAs) derived from prostate cancer patient derived xenografts (PDX) (LuCaP series) and from metastatic CRPC (mCRPC) tissues obtained from Prostate Cancer Biorepository Network (PCBN).